Anti-tumor applications of CeNPs in tumor therapy.
| Treatment | Nanoparticle | Nanoparticle size (nm) | Years (reference) | Mainly role |
|---|---|---|---|---|
| PDT + chemotherapy | MSN-HP-DOX@CeO2 | 100 | 2016 (ref. 39) | Nanocarrier |
| PDT + chemotherapy | PPCNPs-Ce6/FA | 36.1 | 2019 (ref. 40) | Nanocarrier |
| PDT | HA@CQDs-Ce6 | 3–5 | 2018 (ref. 41) | Radiation-protective and nanocarriers |
| PDT + PTT | Bi2S3@Ce6–CeO2NC | 280–340 | 2020 (ref. 42) | Produce oxygen and nanocarrier |
| PTT + chemotherapy | Ru@CeO2-RBT/Res-DPEG | 78 | 2020 (ref. 43) | Produce oxygen and nanocarrier |
| Radiotherapy | NGA-CNPs | 3–5 | 2019 (ref. 44) | Radiation-protective agent and nanocarrier |
| Radiotherapy | CuS@CeO2 | 3–5 | 2020 (ref. 45) | ROS scavengers and nanocarrier |
| Chemotherapy | DNR-CeO2/TiO2NPs | 9.12 | 2020 (ref. 46) | Nanocarrier |
| Chemotherapy | C-TherMods | <25 | 2018 (ref. 47) | Synergistic anticancer |